BRD4 and acute lymphoblastic leukemia: Interestingly, in contrast to its synergy with AraC and GSI+Dex that respectively target DNA replication and NOTCH1 processing pathways that are independent of the p300-BRD4 axis, CHMP5 deficiency did not synergize with the BET inhibitor JQ1 to kill T-ALL cells (Figure S5H and S5I).